BridgeMD
A controlled human rhinovirus infection study of 2-Deoxy-D-Glucose in healthy adults.
EU CTIS ID: 2023-509311-91-01
What this study is testing
To confirm the efficacy of 2-DG compared to placebo for the prevention of rhinovirus-associated illness.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Healthy male or female subjects 18 to 64 (inclusive at screening) years of age. The investigator judges the definition of healthy by detailed medical history and physical examination
- Women of childbearing potential and all males must practice effective contraception during the study and be willing and able to continue contraception for at least 90 days after their last dose of study treatment
- Signed informed consent form prior to any study-related procedures
- Subject is willing and able to tolerate the nasal wash procedure at screening
- Has the ability to communicate well with the investigator in the Dutch language and the willingness and ability to adhere to the prohibitions and restrictions specified in this protocol
You likely can't join if
- Active smoker or history of smoking > 5 pack years
- Upper or lower respiratory tract infection or febrile illness (temperature ≥ 37.9 °C), in the period of 2 weeks prior to study drug administration.
- Presence (at screening) of serum RV-39 neutralizing antibody titer at greater than one in four (1:4) dilution
- Prior inoculation with a virus from the same virus family as the challenge virus
- Hypersensitivity/allergy to any of the investigational product ingredients
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.